ROVI updates its strategy in a meeting with shareholders, investors and analysts
Wed, 23/11/2022 - 00:00
1 minROVI updates its strategy in a meeting with shareholders, investors and analysts
Related
The FDA delays its decision on Risperidone ISM®
Madrid – 21 October, 2021 – Laboratorios Farmacéuticos Rovi, S.A. (“ROVI” or the “...
2 min
21/10/2021
Following the public relevant information published on 26 and on 29 of August 2021 with registered numbers 11377 and 11399 respectively,...
4 min
01/09/2021
Following the public relevant information published on 26 of August 2021 with registered number 11377, Laboratorios Farmacéuticos ROVI, S.A...
2 min
29/08/2021
6s3a6968_1.jpg
TO THE SPANISH NATIONAL SECURITIES MARKET COMMISSION
(COMISIÓN NACIONAL DEL MERCADO DE VALORES)
Madrid, 23 November 2022
In compliance with the reporting requirements provided for in article 227 of the consolidated text of the Securities Market Act, ROVI sends and publishes the attached presentation regarding the update of the company strategy, a presentation that will be distributed today and which can be accessed through the website of the company. Likewise, ROVI will hold an in-person and virtual meeting today with analysts and investors to present said presentation.
Mr. Juan López-Belmonte Encina
Chairman and Chief Executive Officer
Laboratorios Farmacéuticos ROVI, S.A.